Irritable Bowel Syndrome: Latest Advances in Pathophysiology, Diagnosis, and Patient Management

Inflammatory bowel syndrome (IBS) is the most common gastrointestinal disorder seen by primary care providers, yet it remains a source of frustration for both patients and physicians. Recent advances in our understanding of the etiology and pathophysiology of IBS have led to new diagnostic guidelines that avoid unnecessary testing so that IBS is no longer a diagnosis of exclusion. Treatment options are varied and evolving and include pharmacologic and non-pharmacologic options depending on the subtype of IBS and individual patient characteristics. This archived symposium will provide participants with the opportunity to assess new data and remaining challenges in the diagnosis and treatment of patients with IBS via interactive case scenarios.

TARGET AUDIENCE

The goal of this activity is to provide primary care physicians and other healthcare professionals with the most up-to-date clinical knowledge and strategies for the optimal diagnosis and treatment of patients with IBS. No prerequisites required.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. EVALUATE updated IBS diagnostic guidelines, using them to make a positive symptom-based diagnosis.
  2. COMPARE the efficacy and safety of newer treatment options for IBS-D and IBS-C.
  3. RECOGNIZE patient and disease-specific factors that contribute to therapy decision-making in IBS management.

FACULTY

Anthony J. Lembo, MD (Chair)
Associate Professor of Medicine
Harvard Medical School Department of Medicine
Division of Gastroenterology
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Ali Rezaie, MD, MSc, FRCP(C)
Assistant Director
GI Motility Program
Assistant Professor of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Gerald W. Smetana, MD, MACP
Division of General Medicine and Primary Care
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Anthony J. Lembo, MD (Chair)

Consultant/advisor: Alkermes; Allergan; Ardelyx Inc.; Forest Research; Ironwood Pharmaceuticals, Inc.; Prometheus; and Valeant

Ali Rezaie, MD, MSc, FRCP(C)

Speakers’ bureau and consultant/advisor: Valeant (Commonwealth Laboratories LLC and Salix Pharmaceuticals subsidiaries)

Gerald W. Smetana, MD, MACP

Has no financial relationships to disclose

Non-faculty: Lou Settembrino; Christina M. Ohnsman, MD; Sandy Breslow; Leah Johson; Alison Kemp; Bernard M. Abrams, MD; hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from Allergan Inc. and Ironwood Pharmaceuticals.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, Allergan Inc, or Ironwood Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information: There is no fee for this educational activity.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
07/21/2017
Course expires: 
07/20/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
07/21/2017
Course expires: 
07/20/2018
Please login or register to take this course.